(Press-News.org) Reston, VA—A novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published in the May issue of The Journal of Nuclear Medicine. The results of the study suggest that the agent 68Ga-DPI-4452 (Debio 0328) is superior to standard CT imaging in the context of ccRCC. It also allows for significantly faster imaging and, in the future, could be utilized as part of a theranostic pair.
ccRCC accounts for 70-80 percent of renal cell carcinoma cases. Localized disease can be cured with surgery and ablative therapy regimens; however, one-third of patients present with or develop metastases, with poor prognosis. Despite major advances in treatment for renal cell carcinoma, the five-year relative survival rate for distant metastatic disease remains low.
“The carbonic anhydrase IX (CAIX) encoding gene is overexpressed in more than 90 percent of ccRCC cases and is restricted to gastrointestinal tissue, presenting both diagnostic and therapeutic opportunities” said Professor Michael Hofman MBBS, FRACP, FAANMS, nuclear medicine specialist at the Peter MacCallum Cancer Centre in Melbourne, Australia. “In this study, we aim to assess the safety, tolerability, and imaging characteristics of the CAIX-targeting imaging agent 68Ga-DPI-4452 (Debio 0328).”
This ongoing first-in-human GaLuCi study included three patients with histologically confirmed unresectable locally advanced or metastatic ccRCC who had received at least two lines of treatment in a metastatic setting. Patients received 68Ga-DPI-4452 (Debio 0328) and underwent whole-body PET/CT at 15 minutes, and one, two, and four hours after administration. Images from these three initial patients were analyzed, and pharmacokinetics and safety data were assessed.
68Ga-DPI-4452 (Debio 0328) offered outstanding imaging from the earliest time point with sustained tumor uptake up to four hours after administration. The agent was rapidly eliminated from the blood and urine, and no clinically significant toxicity was noted among the patients.
“68Ga-DPI-4452 PET/CT revealed an exceptionally high tumor-to-background ratio, with background tissues nearly invisible with the exception of gastro-intestinal uptake. One-hour after administration was deemed the optimal time point for lesion assessment, which is substantially shorter than the three to seven days needed in previous PET imaging studies using antibody approaches,” said Hofman.
He continued, “Further work is now needed to assess whether this new imaging test could improve patient diagnosis, management, and outcomes. These findings are also encouraging for the evaluation of 177Lu-DPI-4452 (Debio 0228) as a treatment for ccRCC, which will be examined in the second arm of GaLuCi study.”
This study was published online in February 2024.
The authors of “First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinomahttps://doi.org/10.2967/jnumed.123.266515” include Michael S. Hofman, Ben Tran, and Mohammad B. Haskali, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; Darren R. Feldman, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York; Anna Pokorska-Bocci, Solen Pichereau, Jonathan Wessen, Olena Vlasyuk, and Ivana Galetic, Debiopharm International SA, Lausanne, Switzerland; and Richard B. Sparks, CDE Dosimetry Services, Inc., Knoxville, Tennessee.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 16 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
END
New PET agent provides exceptional same-day imaging for clear cell renal cell carcinoma patients
2024-05-07
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Psychedelic therapy and ecological medicine symposium to be held at UCLA
2024-05-07
UCLA Health is set to host a unique symposium this week to explore the evolving research in psychedelic therapies and how combining it with reconnection to natural world could help to amplify their mental health benefits.
The all-day symposium on May 10 at the UCLA campus will bring together the expertise and insights of researchers from UCLA Health’s Psychedelic Studies Initiative and the Jane and Terry Semel Institute for Neuroscience and Human Behaviors as well as filmmakers, psychiatrists, urban planners, indigenous health experts, writers and environmental leaders from throughout the world.
“Promising ...
CU Department of Medicine doctor discusses unintended consequences of patients having immediate access to test results
2024-05-07
In a fast-paced digital age where patients can open their test results as soon as they are available, what happens when a patient reads through complicated results without a physician there to help them understand what it all means? And what happens when a patient misinterprets bad news as good news, or vice versa?
It’s a scenario Benjamin Vipler, MD, confronted after his mom received her colonoscopy results on her health system’s patient portal. Like many patients, she opened up her results before meeting with her clinician and tried to decipher the medical jargon. Thinking the results showed she ...
More feelings of misinformation, more news avoidance, U-M study shows
2024-05-07
As people have more difficulty distinguishing fact from fiction in the United States, they are more likely to feel news fatigue and avoid news altogether, according to a University of Michigan study.
More than an unintentional avoidance because of lack of media exposure, the researchers say people actively avoid news.
The researchers also find that people who identify as strong Democrats begin relying more on nonpartisan news media when feeling misinformed, while people who identify as strong Republicans report using less news media overall, including less conservative news media. Their results are published in Journalism Studies.
"The more confusing ...
Ochsner Health named to Newsweek’s America’s Greatest Workplaces 2024 for Mental Wellbeing
2024-05-07
NEW ORLEANS, La. – Ochsner Health, a leader in patient care, research and education, has been named one of America’s Greatest Workplaces for Mental Wellbeing 2024 by Newsweek and Plant-A Insights Group. The ranking survey conducted included responses from more than 250,000 young professionals and more than 1.5 million company reviews.
Ochsner Health is committed to fostering an environment that prioritizes the mental well-being of each employee through innovative health initiatives, comprehensive support services and a culture ...
Professor emeritus John (Jack) Johnson elected to the National Academy of Sciences
2024-05-07
LA JOLLA, CA—Scripps Research professor emeritus John Johnson, PhD, has been elected to the National Academy of Sciences—one of the highest honors given to scientists. According to the Academy, members are selected “in recognition of their distinguished and continuing achievements in original research.”
“Becoming a member of the Academy is a great honor for me and the 70 graduate students and post docs that have worked in my lab since 1978, as well as numerous collaborators at Scripps and around the world,” says Johnson, who is also the Eldon R. Strahm Professor of Structural Virology in the Department of Integrative Structural ...
University of Nebraska-Lincoln, USDA partner on ground-breaking precision ag research center
2024-05-07
Construction of the National Center for Resilient and Regenerative Precision Agriculture at Nebraska Innovation Campus launched with a ceremonial turning of dirt on May 6.
The state-of-the-art research center is a partnership between the U.S. Department of Agriculture’s Agricultural Research Service, University of Nebraska–Lincoln and Nebraska Innovation Campus. The center will focus on the challenges and opportunities in agricultural innovation for the 21st century.
“There is a long history of scientific innovation and collaboration between ARS and UNL, typical of the USDA-land-grant ...
Two Brookhaven lab scientists named AAAS Fellows
2024-05-07
UPTON, N.Y. — The American Association for the Advancement of Science (AAAS) has recognized two staff scientists from the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory with the distinction of Fellow: Deputy Associate Laboratory Director for High Energy Physics Dmitri Denisov and Senior Chemist Anatoly Frenkel. Each year, AAAS bestows this honor on select members whose “efforts on behalf of the advancement of science, or its applications, are scientifically or socially distinguished.” Marking the 150th anniversary of the program, new fellows ...
Chimps learn and improve tool-using skills even as adults
2024-05-07
Chimpanzees continue to learn and hone their skills well into adulthood, a capacity that might be essential for the evolution of complex and varied tool use, according to a study publishing May 7th in the open-access journal PLOS Biology by Mathieu Malherbe of the Institute of Cognitive Sciences, France and colleagues.
Humans have the capacity to continue learning throughout our entire lifespan. It has been hypothesized that this ability is responsible for the extraordinary flexibility with which humans use tools, a key factor in the evolution of human cognition and culture. ...
AI predicts tumor-killing cells with high accuracy
2024-05-07
MAY 7, 2024, NEW YORK – Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.
Combined with additional algorithms, the predictive model, described in the current issue of the journal Nature Biotechnology, can be applied to personalized cancer treatments that tailor therapy to the unique cellular makeup of each patient's tumors.
“The implementation of artificial intelligence in cellular therapy is new and may be a game-changer, offering new clinical options to patients,” said Ludwig Lausanne’s Alexandre ...
Study provides comprehensive analysis of Rhode Island’s unregulated drug supply
2024-05-07
PROVIDENCE, R.I. [Brown University] — A new analysis revealed the frequency of potentially lethal substances, such as fentanyl and xylazine, in counterfeit pills that had been circulating in Rhode Island’s illicit drug supply.
Study author Dr. Rachel Wightman, an associate professor of epidemiology and emergency medicine at Brown University, said the analysis provides important information about the composition of counterfeit pills, which are designed to replicate legitimate pharmaceutical pills but often lead to adverse health effects.
“The level of detail found in our analysis can help inform treatment conversations and improve patient care,” ...